|
Home : Unsafe Drugs : Vytorin : Law Articles : Three Studies Report Possible Vytorin-cancer Link Three Studies Report Possible Vytorin-cancer LinkThree studies Report Possible Vytorin-cancer linkThree separate studies of the cholesterol-lowering combination drug Vytorin have reported results that show a possible connection between the drug and the development of cancer. Initial concern arose when Dr. Terje Pedersen reported his preliminary results from a study completely independent of a search for a Vytorin-cancer link. Dr. Pedersen's research was concerned with testing if Vytorin could prevent damage to the heart's aortic valve from worsening. Dr. Pedersen found that while the drug did not change the outcome of patients experiencing heart attacks, strokes, or surgeries related to the aortic valve in question, the number of cancer development cases in those taking Vytorin were greater than those patients taking the placebo. Dr Pedersen's research followed 1,873 patients who had developed problems with their aortic valve. Patients were either given Vytorin or a placebo in order to lower their cholesterol. This was done with the idea that this would prevent future heart-related problems from developing in the patients. Initially, the study found that 93 of the patients given Vytorin developed cancer, whereas 65 of those on the placebo developed cancer. This development alarmed other researchers. Other studies taking place at the same time as Dr. Pedersen's began looking to see if their data reflected the same findings as his. Alarmingly, while their research did not find a higher incidence of cancer cases, they found a higher number of cancer deaths in those patients taking Vytorin over the placebo. The final result of Dr. Pedersen's study found that in the patients given Vytorin, 105 developed cancer, as opposed to 70 patients who were given the placebo. These results combined with the two other studies of Vytorin found that cancer related deaths in all three studies were higher. The Medical Community RespondsBut these results did not seem to phase some members of the medical community. Dr. Douglas Weaver, president of the American College of Cardiology, was quoted as saying, “If I was on this medication and it was the only way to get my cholesterol down, I would not change my therapy based on this.” Dr. Weaver's remarks are interesting, considering his connection to big drug companies; the U.S. Senate has demanded that his organization accounts for the money it accepts from major pharmaceutical manufacturers, including Merck, the maker of Vytorin. While there is no conclusive empirical evidence that Vytorin is directly related to the increased numbers of cancer instances and related deaths, there is no denying that there is evidence that suggests that such findings are true. In fact, some researchers are convinced that Vytorin on the whole is an unnecessarily risky medication. Dr. Christer Hoglund, a cardiologist at Sweden's Karolinska Institute has said, “There's no proof that this combination is working,” referring to the combination of drugs in Vytorin. In the meantime, the federal Food and Drug Administration is investigating the possible connection between Vytorin and increased cancer occurrences. It has said that patients should not stop taking Vytorin until there is conclusive evidence. Do You Need Legal Advice Concerning Vytorin?If you have any questions regarding a potential Vytorin Lawsuit, you may contact one of our experienced Vytorin Lawfirms. They can provide you with updates on Vytorin Side Effects, Vytorin-Cancer links, or a possible Vytorin Recall. Contact a Vytorin Attorney using the form at the top of the page. |




